Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer
| Autor: | Gaspar Esquerdo Galiana, Emma Dotor Navarro, Pilar Escudero Emperador, Juan Manuel Campos Cervera, Inmaculada Guasch Jordan, Carles Pericay Pijaume, Manuel Gallén Castillo, Román Bastús Piulats, Eugeni Saigi Grau, Aleydis Pisa Gatell, Jordi Alfaro Gamero |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Leucovorin Administration Oral Antineoplastic Agents Adenocarcinoma Deoxycytidine Tegafur Internal medicine Pancreatic cancer Antineoplastic Combined Chemotherapy Protocols Humans Medicine In patient Survival analysis business.industry General Medicine Middle Aged medicine.disease Survival Analysis Gemcitabine Surgery Pancreatic Neoplasms Clinical trial Treatment Outcome Toxicity Disease Progression Female business Levofolinic acid medicine.drug |
| Zdroj: | Clinical and Translational Oncology. 13:61-66 |
| ISSN: | 1699-3055 1699-048X |
| DOI: | 10.1007/s12094-011-0618-9 |
| Popis: | Advanced pancreatic cancer has a bad prognosis, with a median overall survival (OS) no longer than 4-6 months. Since the end of last century, monotherapy with gemcitabine has remained the elective therapy, but new schedules are needed in order to improve these results. We aim to evaluate the efficacy of tegafur and levofolinic acid (LV) associated with gemcitabine, as well as its toxicity, progression-free survival and OS in advanced pancreatic cancer.An open-label, multicentric, prospective, non-controlled trial was carried out on patients with advanced or disseminated pancreatic cancer. Gemcitabine 1250 mg/m² was administered on the 1st and 8th days of the cycle, tegafur 750 mg/m²/day for 21 consecutive days and LV 25 mg/day continuously, every 28 days, with a maximum of six cycles. The primary variable was tumour overall response rate (ORR). Secondarily, time to progression (TTP), OS and scheme toxicity were determined.Forty patients were recruited; the male/female ratio was 30:10, with a mean age of 61 years. Forty percent had a Karnofsky index of 90% or 100%. Only 11 patients (27%) completed the six cycles of treatment, but more than 50% received three or more cycles. Dose intensity was 89.56% for gemcitabine and 87.36% for tegafur. Efficacy ORR was 22.5% (CI 95%, 6-37%). TTP was 3.87 months (CI 95%, 2.1-5.6), time to treatment failure was 2.97 months (CI 95%, 2.43-4.67) and OS 6.3 months (CI 95%, 4-7). The chemotherapeutic combination was well accepted; most haematologic and non-haematologic toxicities were grade 1 or 2. The most prevalent grade 3/4 toxicities were asthenia (30%), liver biochemistry disorders (25%), diarrhoea (15%) and stomatitis (12%).The administration of gemcitabine, associated with oral tegafur and leucovorin, has activity against advanced pancreatic cancer, with an adequate toxicity profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink